Sign Up
Stories
Breakthrough Animal Study for EVX-B1 Vaccine
Share
Advancements in Antibodies to Protect Im...
Advancements in Cancer Treatment and Mar...
Advancements in Gene Editing and Cancer ...
AB-2100 Phase 1/2 Trial Initiated
AI-Powered Antigen Research Partnership
Atara Biotherapeutics at Health Care Con...
Overview
API
Evaxion Biotech A/S and an unnamed collaborator reveal positive outcomes from animal trials of the EVX-B1 vaccine targeting Staphylococcus aureus, a bacterium causing severe health threats. The potential effectiveness of EVX-B1 antigens in human testing excites the company's Chief Scientific Officer, Birgitte Rønø, amidst rising antibiotic resistance in treating Staphylococcus aureus infections. Leveraging its AI-Immunology™ platform, Evaxion pioneers novel vaccines and immunotherapies for cancer, bacterial, and viral diseases.
Ask a question
How might the success of the EVX-B1 vaccine impact the landscape of infectious disease treatment and antibiotic resistance?
In what ways could the AI-Immunology™ platform revolutionize vaccine development beyond Staphylococcus aureus?
What challenges could arise in transitioning from successful animal trials to human trials for the EVX-B1 vaccine?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jan 2024
Feb 2024
Mar 2024
Coverage